<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282151</url>
  </required_header>
  <id_info>
    <org_study_id>DOCET_L_05478</org_study_id>
    <nct_id>NCT01282151</nct_id>
  </id_info>
  <brief_title>TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer</brief_title>
  <acronym>TRAIL</acronym>
  <official_title>A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is:

        -  A multicenter, prospective, randomized, phase 3 trial.

        -  To prove non-inferiority of Taxotere/Cisplatin compared to Pemetrexed/Cisplatin as a
           front line treatment of patients with non-squamous cell lung cancer.

        -  276 patients will be recruited.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel is being used in 60mg/m2 3 weekly dosage in Japan and several east Asian
      institutions. Docetaxel 60mg/m2 and Cisplatin 70 mg/m3 3 weekly regimen will be compared to
      Pemetrexed 500mg/m2 and Cisplatin 70 mg/m2 3 weekly regimen in first line NSCLC with
      non-squamous histology.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruitment due to approval of maintenance pemetrexed treatment
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>one year</time_frame>
    <description>months after beginning of first cycle chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (months from the beginning of first cycle chemotherapy)</measure>
    <time_frame>three years</time_frame>
    <description>months from the beginning of first cycle chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Profile</measure>
    <time_frame>four months</time_frame>
    <description>Toxicity using CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>6-7th week</time_frame>
    <description>Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Carcinoma, Non Small Cell Lung</condition>
  <arm_group>
    <arm_group_label>Taxotere</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel plus Cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed plus Cisplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks</description>
    <arm_group_label>Taxotere</arm_group_label>
    <other_name>Taxotere(R)</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks</description>
    <arm_group_label>Pemetrexed</arm_group_label>
    <other_name>Alimta (R)</other_name>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 18 years old

          -  ECOG performance status 0-2

          -  Non-squamous cell type non-small cell lung cancer (NSCLC)

          -  Stage IV, Stage IIIB cannot be treated with curative intent or Relapsed after surgery
             or radiation therapy

          -  No prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation
             treatment. The last dose of adjuvant chemotherapy should be at least 6 months earlier
             from randomization, and the regimen should not contain docetaxel or pemetrexed.

          -  No prior immunotherapy, biologic therapy

          -  Measurable lesion with Response Evaluation Criteria in Solid Tumors (RECIST) version
             1.1

          -  Hemoglobin &gt;=9.0g/dl, Platelet &gt;=100,000/uL, neutrophil &gt;=1,500 /uL Creatinine &lt;=1.5 x
             upper normal limit or creatinine clearance &gt;=60 mL/min Bilirubin &lt;=1.5 x upper normal
             limit, Transaminases &lt;=2 x upper normal limit Alkaline phosphatase &lt;=2 x upper normal
             limit

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnancy, Lactating woman

          -  Woman in child bearing age who refuses to do pregnancy test

          -  Moderate or greater than grade 1 motor or sensory neurotoxicity

          -  Hypersensitivity to taxane

          -  Comorbidity or poor medical conditions

          -  Other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in
             situ)

          -  Concurrent treatment with other investigational drugs within 30 days before
             randomization

          -  Active treatment with other anticancer chemotherapy

          -  EGFR mutation (exon 19 deletion, L858R, L861Q, G719A/C/S)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Chul Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Chonnam National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeonnam</state>
        <zip>519-709</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Daegu</city>
        <state>Kyungpook</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dankook University Hospital</name>
      <address>
        <city>Cheonan</city>
        <zip>330-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Center</name>
      <address>
        <city>Daegu</city>
        <zip>700-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam Univeristy Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonkwang University Hospital</name>
      <address>
        <city>Iksan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konkuk university medical center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <last_update_submitted>July 13, 2015</last_update_submitted>
  <last_update_submitted_qc>July 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Young-Chul Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non Squamous cell</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 27, 2015</submitted>
    <returned>August 21, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

